

Company Overview

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington's disease and myotonic dystrophy, as well as a variety of other genetic disorders.

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

Sep 28 2021, 4:05 PM EDT

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 15 2021, 4:05 PM EDT

NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

Sep 14 2021, 8:00 AM EDT

Stock Overview

Symbol	NBSE
Exchange	Nasdaq
Market Cap	136.76m
Last Price	\$4.18
52-Week Range	\$3.26 - \$12.89

10/21/2021 04:00 PM EDT

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-535-7746
daniel@lifesciadvisors.com

Management Team

Dietrich A. Stephan, Ph.D.

Chairman & Chief Executive Officer, Founder

Robert Friedlander, M.D.

Consulting Chief Medical Officer

William Mann, Ph.D.

Chief Operating Officer

Kia Motesharei, Ph.D.

Chief Business and Strategy Officer

Sandra Rojas-Caro, M.D.

Chief Medical Officer

Anthony Rossomando, Ph.D.

Chief Technology Officer

Robert Zamboni, Ph.D.

Chief of Preclinical Development

NeuBase Therapeutics, Inc.

350 Technology Drive
Pittsburgh, PA 15219

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.